Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis

Abstract : Background: In the current context of personalized medicine, one of the major challenges in the management of rheumatoid arthritis (RA) is to identify biomarkers that predict drug responsiveness. From the European APPRAISE trial, our main objective was to identify a gene expression profile associated with responsiveness to abatacept (ABA) + methotrexate (MTX) and to understand the involvement of this signature in the pathophysiology of RA. Methods: Whole human genome microarrays (4 × 44 K) were performed from a first subset of 36 patients with RA. Data validation by quantitative reverse-transcription (qRT)-PCR was performed from a second independent subset of 32 patients with RA. Gene Ontology and WikiPathways database allowed us to highlight the specific biological mechanisms involved in predicting response to ABA/MTX.
Liste complète des métadonnées

Littérature citée [47 références]  Voir  Masquer  Télécharger

https://hal-normandie-univ.archives-ouvertes.fr/hal-02337207
Contributeur : Nicolas Vergne <>
Soumis le : mardi 29 octobre 2019 - 12:45:53
Dernière modification le : vendredi 15 novembre 2019 - 14:50:13

Fichier

Aba-ArtResTher2017.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

C. Derambure, G. Dzangue-Tchoupou, C. Bérard, N. Vergne, M. Hiron, et al.. Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis. Arthritis Research and Therapy, BioMed Central, 2017, 19 (1), ⟨10.1186/s13075-017-1319-8⟩. ⟨hal-02337207⟩

Partager

Métriques

Consultations de la notice

8

Téléchargements de fichiers

20